Brief: Cyclerion Announces Positive Data From IW-6463 CNS Translational Pharmacology Study In Healthy Elderly Subjects

Korsana Biosciences

14/10/2020 13:35

Oct 14 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION ANNOUNCES POSITIVE DATA FROM IW-6463 CNS
TRANSLATIONAL
PHARMACOLOGY STUDY IN HEALTHY ELDERLY SUBJECTS
    * CYCLERION - PROCEEDING WITH UPCOMING PHASE 2 CLINICAL
TRIALS IN
MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS, STROKE-LIKE
EPISODES
    * CYCLERION THERAPEUTICS - CONFIRMED BLOOD-BRAIN-BARRIER
PENETRATION, DESIRED CNS EXPOSURE LEVELS, TARGET ENGAGEMENT AND
FAVORABLE SAFETYPROFILE
    * CYCLERION - PROCEEDING WITH UPCOMING PHASE 2 CLINICAL
TRIALS IN
ALZHEIMER'S DISEASE WITH VASCULAR PATHOLOGY
    * CYCLERION THERAPEUTICS INC - EXPECT TO INITIATE ENROLLMENT
OF
MELAS STUDY LATER THIS YEAR
    * CYCLERION THERAPEUTICS INC - SUBJECTS RECEIVING IW-6463
SHOWED
MEANINGFUL IMPROVEMENTS IN CERTAIN NEUROPHYSIOLOGICAL &
OBJECTIVE PERFORMANCE MEASURES
    * CYCLERION THERAPEUTICS-PLANS TO USE FINDINGS OF STUDY FOR
INITIATION OF PHASE 2 CLINICAL TRIAL IN ALZHEIMER'S DISEASE WITH
VASCULAR PATHOLOGY IN 2021
    * CYCLERION THERAPEUTICS INC -WILL EVALUATE POTENTIAL OF
IW-6463
TO PROVIDE CLINICAL BENEFIT FOR PEOPLE SUFFERING FROM A RANGE OF
SERIOUS CNS DISEASES

Source text for Eikon:  ID:nGNX5RF2bw 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))